Mostrar el registro sencillo del ítem

dc.contributor.authorVerde Rello, Zoraida 
dc.contributor.authorGarcía de Diego, Laura
dc.contributor.authorChicharro, Luis M.
dc.contributor.authorBandrés, Fernando
dc.contributor.authorVelasco González, Verónica 
dc.contributor.authorMingo Gómez, María Teresa 
dc.contributor.authorFernández Araque, Ana María 
dc.date.accessioned2022-05-10T08:14:06Z
dc.date.available2022-05-10T08:14:06Z
dc.date.issued2019
dc.identifier.citationInternational Journal of Environmental Research and Public Health, 2019, vol. 16, n. 21, 4190es
dc.identifier.issn1660-4601es
dc.identifier.urihttps://uvadoc.uva.es/handle/10324/53285
dc.descriptionProducción Científicaes
dc.description.abstractOlder adults are at increased risk of several cytochrome P450 (CYP) drug interactions that can result in drug toxicity, reduced pharmacological effect, and adverse drug reactions. This study aimed to assess the prevalence of potential CYP interactions referring to the most clinically relevant drugs and exploring the relationship between them and quality of life and physical performance in Spanish octogenarians. Institutionalized and community-dwelling octogenarians (n = 102) treated at three primary care centers, were recruited by a research nurse. Anthropometric measurements, chronic diseases, prescribed drugs, quality of life, physical performance, mobility skills, hand grip strength and cognitive status data were collected. Potential CYP drug-drug interactions (DDIs) were selected referring to the main CYP implicated in their metabolism. The 72.2% of recruited octogenarians presented potentially inappropriate CYP inhibitor-substrate or CYP inductor-substrate combinations. Analyzing the EuroQol Visual Analogue scale (EQ-VAS) results, patients with a potential CYP DDI perceived worse health status than patients without it (p = 0.004). In addition, patients with a potential CYP DDI presented worse exercise capacity, kinesthetic abilities, or mobility than those who didn’t present a potential interaction (p = 0.01, p = 0.047, and p = 0.02, respectively). To investigate and control factors associated with loss of muscle strength and poor quality of life, polypharmacy and DDIs could help institutions in the management of physical frailty.es
dc.format.mimetypeapplication/pdfes
dc.language.isoenges
dc.publisherMDPIes
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.classificationCytochromeses
dc.subject.classificationCitocromoses
dc.subject.classificationDrug interactionses
dc.subject.classificationInteracciones medicamentosases
dc.subject.classificationPolypharmacyes
dc.subject.classificationPolifarmaciaes
dc.titlePhysical performance and quality of life in older adults: Is there any association between them and potential drug interactions in Polymedicated Octogenarians?es
dc.typeinfo:eu-repo/semantics/articlees
dc.rights.holder© 2019 The Authorses
dc.identifier.doi10.3390/ijerph16214190es
dc.relation.publisherversionhttps://www.mdpi.com/1660-4601/16/21/4190/htmes
dc.peerreviewedSIes
dc.description.projectFundación Científica Caja Rural de Soria (project 00200200227)es
dc.rightsAtribución 4.0 Internacional*
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersiones


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem